• News
  • BioTech

Lumena dosing patients in liver treatment clinical trial

San Diego-based Lumena Pharmaceuticals on Friday announced the dosing of the first patient in the INDIGO Phase 2 clinical trial of its lead drug candidate, LUM001, in children with progressive familial intrahepatic cholestasis (PFIC).

To continue reading, subscribe now
log in to your account
User Response
0 UserComments
Subscribe Today!